Mustang Bio, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Manuel Litchman
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 377 Plantation Street Worcester MA United States of America 01605
- IPO Date
- Aug 22, 2017
- CIK
- 0001680048
- Website
- mustangbio.com
- Similar Companies
- Business
- Mustang Bio, Inc. is a clinical-stage biopharmaceutical entity committed to transforming scientific advancements in cell therapies into potential treatments for aggressive cancers and autoimmune disorders. The company’s pipeline prioritizes chimeric antigen receptor (CAR) T cell therapies targeting both hematologic and solid tumor indications. Its leading programs include MB-106, a CD20-directed CAR T cell therapy in development for B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases, which has received Orphan Drug Designation for Waldenstrom macroglobulinemia and Regenerative Medicine Advanced Therapy (RMAT) designation for specific lymphomas. Mustang Bio is also advancing MB-101, an IL13Rα2-targeted CAR T cell therapy for glioblastoma and high-grade astrocytoma, which recently secured Orphan Drug Designation for these conditions. Complementing this is MB-108, a next-generation oncolytic herpes simplex virus, granted Orphan Drug Designation for malignant glioma. A combination therapy, MB-109, which pairs MB-101 with MB-108 to treat recurrent glioblastoma and high-grade astrocytoma, has received FDA acceptance for an Investigational New Drug (IND) application. Mustang Bio partners with renowned medical institutions, including City of Hope and Fred Hutchinson Cancer Center, to advance its therapeutic candidates. The company was established in 2015 and maintains its corporate headquarters in Waltham, Massachusetts, having recently completed a strategic sale of its Worcester manufacturing facility. Recent corporate actions include regaining compliance with Nasdaq listing standards and executing a reverse stock split. As a clinical-stage company, Mustang Bio's financial strategy focuses on securing funding through collaborations, grants, and equity financing to propel its research and development initiatives, rather than product sales revenue.
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection
MindBio Announces Closing of Private Placement
MindBio Announces Upsize to Private Placement up to $1.5 Million
Critical Contrast: Mustang Bio (NASDAQ:MBIO) & AstraZeneca (NASDAQ:AZN)
MindBio Announces Private Placement to Raise up to $650,000
MindBio Advances Large-Scale Deployment of Voice Intoxication Detection Through Integrated Edge AI Hardware-Software Platform
CSE Bulletin: Consolidation - MindBio Therapeutics Corp. (MBIO)
Talisker Receives Assay Results from 1105 Level Lateral Development at the Mustang Mine
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy
Dow Dips 1%; Mustang Bio Shares Spike Higher
This BlackRock stock just spiked over 300%
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
Mustang Bio Announces Closing of $8 Million Public Offering
Mustang Bio Announces Pricing of $8 Million Public Offering
Mustang Bio Announces Reverse Stock Split